Swisscanto Holding

Founded in 2016, ANYbotics develops autonomous legged robots designed for industrial applications. These robots are equipped with features such as docking stations, robust sensing capabilities, and waterproofing. They also offer tools for reading instruments, monitoring equipment health, detecting events, and inspecting complex environments. The company aims to improve worker safety, increase productivity, and support sustainable operations in industries like oil and gas, power, mining, chemicals, construction, and transportation.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Nagi Bioscience develops automated testing devices that use Caenorhabditis elegans worms to screen molecules for pharmaceutical, chemical and cosmetic applications. Its Organism-on-Chip platform combines whole-organism biology with an automated in vitro workflow for culture, treatment, and multi-parametric analysis, enabling toxicity testing, drug discovery, and anthelmintic screening. The technology links in vivo worm models with a fully automated platform to observe biological responses that emerge at the whole-organism level. The company is headquartered in Lausanne, Switzerland.

Founded in 2016, ANYbotics develops autonomous legged robots designed for industrial applications. These robots are equipped with features such as docking stations, robust sensing capabilities, and waterproofing. They also offer tools for reading instruments, monitoring equipment health, detecting events, and inspecting complex environments. The company aims to improve worker safety, increase productivity, and support sustainable operations in industries like oil and gas, power, mining, chemicals, construction, and transportation.

ecoRobotix is a Swiss developer of autonomous weeding machines for row crops, meadows, and intercropping cultures. The company builds systems that use vision, cameras, GPS RTK, and sensors to follow crop rows, identify weeds, and guide robotic arms to apply micro-doses of herbicide directly to target weeds, enabling precision spraying and reducing chemical use. Its solutions aim to lower environmental impact and farming costs by enabling ecological and economical weed control. Founded in 2011 and based in Yverdon-les-Bains, Switzerland, ecoRobotix markets platforms that cover inter-row spaces as well as crop rows, delivering substantial reductions in chemical applications while maintaining yields.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Sulzer Schmid is an independent Swiss technology company specializing in advanced solutions for the inspection and analysis of rotor blades. The company has developed a cloud-based platform that provides comprehensive inspection tools and data analytics, enabling windmill operators to monitor the health status of their rotor blades. This platform offers a transparent view of blade conditions across an entire fleet, allowing customers to capture visual data, process images, and generate customizable reports. Through its innovative technology, Sulzer Schmid empowers operators to track damage progression over time, facilitating informed decision-making regarding maintenance and repairs.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, Versantis aims to address significant unmet medical needs for patients globally. Its lead candidate, VS-01, is currently in preclinical development and has the potential to be the first treatment for acute liver disease while simultaneously supporting multiple failing organs. VS-01 has received Orphan Drug Designation for its application in acute liver failure. The company also has additional treatments in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent substantial market opportunities and underscore Versantis' commitment to improving patient outcomes for millions affected by liver conditions and related disorders.

SWISSto12 SA is a Swiss company that specializes in the manufacture and supply of radio frequency (RF) and microwave components and systems. Founded in 2011 as a spin-off from the Swiss Federal Institute of Technology in Lausanne, the company is based in Renens, Switzerland, with additional offices in Santa Clara, California, and Rehovot, Israel. SWISSto12 offers a range of products including various types of horn antennas, airborne antenna arrays, waveguide antennas, and custom-designed antennas and filters. The company is known for its innovative use of metal-coated 3D printing technology, which enhances design flexibility while reducing costs, lead times, and weight. Its offerings extend to polymer and metal waveguide products, as well as integration and testing services. SWISSto12 serves clients in satellite communications, airborne satellites, and research centers, and is also developing software solutions for material properties extraction.